Armendáriz-Castillo Isaac, García-Cárdenas Jennyfer, Espinosa Pamela, Hidalgo-Fernández Katherine, Peña-Zúñiga Lizbeth, Martínez Ronie, Moromenacho Juan, Herrera-Yela Andrés, Cruz-Varela Jonathan, Saucedo-Sariñana Anilú, Cerdán María-Esperanza, López-Cortés Andrés, Guerrero Santiago
Laboratorio de Ciencia de Datos Biomédicos, Facultad de Ciencias Médicas de la Salud y de la Vida, Universidad Internacional del Ecuador, Quito, Ecuador.
Centro Interdisciplinar de Química e Bioloxía (CICA), Campus de Elviña, Universidade da Coruña, A Coruña, Spain.
PLoS One. 2025 Feb 21;20(2):e0314012. doi: 10.1371/journal.pone.0314012. eCollection 2025.
Alternative Lengthening of Telomeres (ALT) is a telomerase-independent mechanism deployed by several aggressive cancers to maintain telomere length. This contributes to their malignancy and resistance to conventional therapies. In prior studies, we have identified key proteins linked to the ALT process using multi-omic data integration strategies. In this work, we combined metabolomic datasets with our earlier results to identify targetable metabolic pathways for ALT-positive tumors. 39 ALT-related proteins were found to interact with 42 different metabolites in our analysis. Additional networking analysis revealed a complex interaction between metabolites and ALT-related proteins, suggesting that pan-cancer oncogenes may have an impact on these pathways. Three metabolic pathways have been primarily related with the ALT mechanism: purine metabolism, cysteine and methionine metabolism, and nicotinate and nicotinamide metabolism. Lastly, we prioritized FDA-approved drugs (azathioprine, thioguanine, and mercaptopurine) that could target ALT-positive tumors through purine metabolism. This work provides a wide perspective of the metabolomic pathways associated with ALT and reveals potential therapeutic targets that require further experimental validation.
端粒替代延长(ALT)是几种侵袭性癌症所采用的一种不依赖端粒酶的机制,用于维持端粒长度。这有助于它们的恶性程度以及对传统疗法的抗性。在先前的研究中,我们使用多组学数据整合策略鉴定了与ALT过程相关的关键蛋白。在这项工作中,我们将代谢组学数据集与我们早期的结果相结合,以鉴定ALT阳性肿瘤的可靶向代谢途径。在我们的分析中,发现39种与ALT相关的蛋白与42种不同的代谢物相互作用。额外的网络分析揭示了代谢物与ALT相关蛋白之间的复杂相互作用,表明泛癌癌基因可能对这些途径有影响。三种代谢途径主要与ALT机制相关:嘌呤代谢、半胱氨酸和甲硫氨酸代谢以及烟酸和烟酰胺代谢。最后,我们确定了可通过嘌呤代谢靶向ALT阳性肿瘤的FDA批准药物(硫唑嘌呤、硫鸟嘌呤和巯嘌呤)。这项工作提供了与ALT相关的代谢组学途径的广泛视角,并揭示了需要进一步实验验证的潜在治疗靶点。